Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update

Overview of attention for article published in Journal of Clinical Oncology, July 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 1 news outlet
policy: 1 policy source
twitter: 91 X users

patent: 2 patents
facebook: 1 Facebook page
guideline: 4 clinical guideline sources

Readers on

mendeley: 292 Mendeley

So far, Altmetric has seen 100 X posts from 91 X users, with an upper bound of 608,921 followers.

@financebully SoC in first line is endocrine therapy plus cdk4/6 https://t.co/pwbjW5RxKy https://t.co/ADNmtvCa63. “64% of cases with a prior test result of HER2 IHC 0 were HER2-low/ultralow by central testing.” HER2 ultralow IS ihc 0 at times.

RT @DFCI_BreastOnc: #ASCO Guideline Update on Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growt…

#ASCO Guideline Update on Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer from @DrHBurstein et al #bcsm #MBC #breastcancer

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 96 additional X posts.